SOLSTICE

Clinical Trial

NCT03584165 Recruiting, Active

SOLSTICE

A Long-term Follow-up Study to Evaluate the Safety and efficacy of Retinal Gene Therapy in Subjects with choroideremia treated previously with Adeno-Associated Viral Vector Encoding Rab Escort Protein-1 (AAV2-REP1) in an Antecedent Study.

Phase 3

Interventional

Disease

Disease type

Choroideremia

Orphan drug recognition

Yes

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

01/01/2017

Closing date

04/06/2026

Inclusion criteria :

Exclusion criteria :

Funding

industry

Members involved

Main investigators

Dr Florian Gekeler

Germany

Others investigators

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

Substitute

Germany

Dr Susanne KOHL

Substitute

Germany

Genetic Diagnostics (TWG6), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Dr Philipp Herrmann

Substitute

Germany

CPMS & Digital Medecine (TWG10), Genetic Diagnostics (TWG6), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Michael LARSEN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Working Group Leader

Pr Isabelle MEUNIER

Representative

France

Retinal Rare Eye Diseases (WG1)

Dr Joni Turunen

Representative

Finland

Genetic Diagnostics (TWG6), Pediatric Ophthalmology Rare Diseases (WG3), Research (TWG8)

Pr Frank Holz

Representative

Germany

Pr Isabelle Audo

Representative

France

Genetic Diagnostics (TWG6), Low Vision Daily Life and Patients Groups (TWG5), National Integration (TWG9), Neuro-Ophthalmology Rare Diseases (WG2), Pediatric Ophthalmology Rare Diseases (WG3), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)

Pr Frans Cremers

Netherlands

Genetic Diagnostics (TWG6), Neuro-Ophthalmology Rare Diseases (WG2), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)